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a  b  s  t  r  a  c  t
Ezrin  is  a member  of the ezrin–radixin–moesin  family  of  proteins.  Overexpression  of  ezrin
protein  might  play  an  important  role  in  the  process  of tumor  cell  invasion  and  metastasis.
Non-melanoma  skin  cancer  (NMSC)  is the most  common  form  of  cancer  seen  in population.
The  term  NMSC  can theoretically  be applied  to all  cutaneous  cancers  excluding  melanoma.
The  aim  of  the  study  was to  evaluate  the  prognostic  value  of  ezrin  expression  in  basal  cell
carcinoma  (BCC),  cutaneous  squamous  cell  carcinoma  (SCC),  seborrheic  keratosis  (SK)  and
keratoacanthoma (KA).  This  retrospective  study  included  76  parafﬁn  blocks  classiﬁed  into:
group I (20  parafﬁn  blocks  of  BCC),  group  II (20  parafﬁn  blocks  of SCC),  group  III (12 parafﬁn
blocks of  SK),  group  IV (14 parafﬁn  blocks  of  KA)  and  group  V (10  parafﬁn  blocks  of normal
healthy  skin  were  used  as a control  group).  All were  subjected  to the ordinary  hematoxylin
and  eosin  stain  (H&E)  and  immunohistochemical  staining  for  ezrin.  This  study  revealed  a
statistically signiﬁcant  difference  between  ezrin  expression  in  different  tumor  groups  and
controls. The  expression  of  ezrin  in  SCC  was  higher  than  in  BCC,  SK  and  KA.  There  was  a
statistically  signiﬁcant  difference  of ezrin  expression  in  different  tumor  groups  regarding
both membranous  and cytoplasmic  expression  of  ezrin.  The  current  study  suggested  that
dysregulation  of  ezrin  may  be  important  in  the development  of  cutaneous  epithelial  malig-
nancies  and  tumor  grade.  Immunohistochemical  localization  of ezrin  may  be  useful  marker
in the  differentiation  between  cutaneous  SCC  and  KA.
© 2014  Saudi  Society  of  Microscopes.  Published  by  Elsevier  Ltd.  All  rights  reserved.. Introduction
Ezrin is a member of the ezrin–radixin–moesin (ERM)
amily of proteins, which link the actin-containing
ytoskeleton to the plasma membrane. It is functionally
nvolved in signaling events that regulate cell survival,
ell proliferation, migration, and cellular morphogenesis.
zrin is expressed in a variety of normal and neoplastic
ells, including many types of epithelial, lymphoid, and
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213-879X/© 2014 Saudi Society of Microscopes. Published by Elsevier Ltd. All riglial cells [1]. Overexpression of ezrin protein is corre-
lated with the metastatic potential in several cancers [2–4]
through  regulating adhesion molecules and signal trans-
duction pathways and affection of cell–cell and cell–matrix
interactions [2].
Basal  cell carcinoma is the most common skin neo-
plasm in humans, and is usually characterized by local
aggressiveness with a slight metastatic potential. BCC is a
slow-growing tumor but, if not treated properly, the inva-
sion  of subcutaneous adipose tissue, muscle, cartilage and
even  bones may  occur [5]. During the process of inﬁltration,
neoplastic cells have to pass through various barriers such
as  the extracellular matrix, interstitial tissue and basement
ghts reserved.
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membrane [6]. Cutaneous SCC is a malignant tumor that
arises  from the keratinizing cells of the epidermis or its
appendages. It is locally invasive tumor and has the poten-
tial  to metastasize to other organs of the body [7]. SKs
are  non-cancerous (benign) skin growth that some peo-
ple  develop as they age. They often appear on the back or
chest,  but they can occur on any part of the body. SK grows
slowly,  in groups or singly [8]. KA is a rapidly growing skin
tumor  which is characterized by a distinct keratin-ﬁlled
cup-shaped appearance, and spontaneous regression is a
unique  clinical feature. Most KA cause only minimal skin
destruction, but a few behave more aggressively and can
spread  to lymph nodes. In addition, the histopathologi-
cal ﬁndings of KA are occasionally indistinguishable from
those  of well-differentiated SCC, leading some authors to
believe  that KA is a subtype of SCC [9,10].
Little is known about the distribution of ezrin in normal
epidermis and NMSC; therefore there is a need to study
the  expression of ezrin in normal skin and epithelial skin
tumors  and to explore its value.
2. Materials and methods
The  current retrospective case controlled study was
conducted on 76 cases with available parafﬁn blocks and
clinical  data collected from the archives of the Pathology
Department, Faculty of Medicine, Tanta University Hos-
pitals.  The blocks were divided into: group I (20 parafﬁn
blocks of BCC), group II (20 parafﬁn blocks of SCC), group
III  (12 parafﬁn blocks of SK), group IV (14 parafﬁn blocks
of  KA) and group V (10 parafﬁn blocks of normal healthy
skin were used as a control group). The control group was
age  and sex matched to the cases whose parafﬁn blocks
were the subjects of the current study. Specimens of the
control  group were obtained from the normal skin spec-
imens  received during plastic operations. All blocks were
sectioned and stained with H&E for detection of general
histopathological criteria and immunohistochemistry for
ezrin,  by the following steps.
3–5 m sections were deparafﬁnized in xylene, and
then rehydrated in descending concentration of alcohols
[ethanol]. Sections were incubated in 0.3% H2O2 for 30 min
to  block endogenous peroxidases. Slides were then washed
with  phosphate-buffered saline (PBS) and heated in an 830-
W  microwave oven for at least 15 min  in 10 mM sodium
citrate buffer (pH 6.0) for antigen retrieval. Sections were
incubated with the primary antibody (Mouse, anti-ezrin
Monoclonal antibody dilution 1:100, Lab Vision Corpora-
tion  Fremont, CA, USA; Catalog #MS-661-P0) overnight at
4 ◦C. For the negative control, the primary antibody was
replaced with PBS. Biotinylated Goat anti-polyvalent, ready
to  use available form (Lab Vision Corporation, USA) sec-
ondary  antibody was added followed by incubation for
10  min  at room temperature. The color was developed
using diaminobenzidine (DAB) as a chromogen. Slides were
extensively washed with PBS after each step. Finally they
were  counter-stained with Meyer’s hematoxylin. The inter-
nal  positive control was the sweat glands in each section.
The  ezrin showed cytoplasmic expression. The stained sec-
tions  were scanned using the 4× objective lens to allocate
the areas of highest positivity was evaluated in the lesionalnd Ultrastructure 2 (2014) 67–76
squamous epithelial cells, basaloid cells when appropri-
ate  as well as the adjacent epidermis (when available) and
the  underlying inﬂammatory inﬁltrate. For each of these
3  components; the intensity was evaluated using the pos-
itivity  of the sweat glands epithelium. The percentage of
positive  cells was  determined in 10 high power ﬁelds and
the  mean percentage for each type of cells was recorded
separately in each section. The overall intensity of the stain
in  each section was assessed subjectively, in relation to
the  positivity of the sweat glands. Then the extent of pos-
itivity  for both components were scored as follow: 0: no
immunoreactivity; 1: <10% of the cells positive; 2: 10–25%
of  cells stained; 3: 25–50% of cells stained; 4: more than
50%  of cells stained. In healthy controls the immunoreactiv-
ity limited to sweat glands which considered non-speciﬁc
reaction which was used as a reference where the investi-
gated cells were considered positive if the intensity of their
staining  is higher than the intensity of the sweat glands
[11]. The intensity of the stain was classiﬁed into negative
(score zero = the intensity of the sweat gland staining), mild
(score  1), moderate (score 2) and intense (score 3). Score 1,
2  and 3 were higher than the sweat gland staining intensity.
An  immunoreactivity index was  obtained by multiplying
the extent by the intensity of staining and the range of score
was;  negative: 0–3, mild >3–5, moderate >5–9, strong >9
[11].
2.1.  Statistical analysis
All  data obtained were transferred to the statistical
package for the social sciences version 15 (IBM Co., New
York,  USA) for analysis. Data were summarized using mean,
standard  deviation (mean ± SD) for quantitative variables.
Comparison between non-parametric quantitative vari-
ables  were made by Kruskal–Wallis ANOVA test. Statistical
signiﬁcance was  determined at a level of P < 0.05* and
highly signiﬁcance at a level of P ≤ 0.001**.
3.  Results
The demographic data of the studied groups were rep-
resented in Table 1.
3.1.  Histopathological results
Histopathological data of the tumors were represented
in Table 1 and from Figs. 1a–4c.
3.2. Immunohistochemical results
In healthy controls, the ezrin immunoreactivity limited
to  sweat glands epithelium which considered non-speciﬁc
negative reaction (Fig. 5). The ezrin lesional score expres-
sion  in SCC ranged from 2 to 9 with mean ± SD 6.40 ± 2.91,
in  BCC, it ranged from 3 to 9 with mean ± SD 6.30 ± 1.70, in
SKs  it ranged from 1 to 6 with mean ± SD 3.00 ± 2, in KA it
ranged  from 4 to 9 with mean ± SD 6.29 ± 2.06 and in con-
trol  group it ranged from 2 to 3 with mean ± SD 2.40 ± 0.55
there  were statistically highly signiﬁcant differences when
comparing its expression between different tumor groups
and  controls (P = 0.001). The highest mean value of lesion
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Table 1
The  demographic and histopathological data of the studied groups.
Group
SCC BBC SK KA Normal
Age Range 40–75 45–86 50–80 40–80 36–68
Mean  ± SD 60.50 ± 12.41 62.90 ± 15.63 63.67 ± 10.01 62.14 ± 14.26 60.30 ± 10.40
Sex Male N (%) 10 (50%) 14 (70%) 6 (50% 14 (100%) 4 (40.0% 48 (63.3%)
Female  N (%) 10 (50%) 6 (30%) 6 (50%) 6 (60.0%) 28 (36.8%)
Site  Head and neck N (%) 15  (75%) 20  (100%) 8  (66.6%) 10  (71.4%) 10 (100.0%) 63 (74.5%)
Breast  N (%) –  – 2 (16.7) 2 (1.8%)
Trunk  N (%) – – 2 (16.7) 2 (7.3%)
Lower  limb N (%) 5 (25%) – 4 (28.6) 9 (16.4%)




















































Fig. 1. (a) Well differentiated squamous cell carcinoma (grade I) with prominent cell nest formation (×40, H&E). (b) Moderately differentiated squamous
cell  carcinoma (grade II) with keratinization in some neoplastic cellular masses (×40, H&E). (c) Poorly differentiated squamous cell carcinoma (grade III)
with  high grade nuclear features and eosinophilic dyskeratotic cytoplasm, no keratinization could be observed (×40, H&E).
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Fig. 2. (a) Nodular basal cell carcinoma showing nodules of basaloid cells inﬁltrating the epidermis with peripheral palisading (×40, H&E). (b) Nodulocystic
basal  cell carcinoma showing nodules of basaloid cells with large cystic spaces (×40, H&E). (c) Morphea-like basal cell carcinoma with trabeculae of basaloid
cells  surrounding by dense desmoplastic reaction compressing the trabeculae (×40, H&E). (d) Superﬁcial basal cell carcinoma with buds of basaloid cells
in  the superﬁcial dermis between the rete ridges of the epidermis (×40, H&E).
Table 2
Comparison of mean lesion, inﬂammation and adjacent epidermis scores as regard ezrin expression in relation to type of the lesion.
Type of lesion Lesion score Inﬂammation score Adjacent epidermis
Range Mean ± SD Range Mean ± SD Range Mean ± SD
SCC 2–9 6.40 ± 2.91 1–9 7.30 ± 2.63 2–9 4.50 ± 2.68
BCC  3–9 6.30 ± 1.70 2–9 6.10 ± 2.38 1–6 3.17 ± 2.23
SK  1–6 3.00 ± 2 1–9 3.17 ± 2.99 0–4 1.33 ± 1.51
KA  4–9 6.29 ± 2.06 4–9 6.43 ± 2.51 1–6 3.29 ± 2.06
Control  2–3 2.40 ± 0.55 – – – –
Kruskal–Wallis  test 10.11 5.36 2.14
P-value  0.001* 0.020* 0.063
* P value <0.05 was considered signiﬁcant.
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fig. 3. (a) Acanthotic seborrheic keratosis with marked acanthosis and 
panning  the whole thickness of the lesion with horn cysts and papilloma
apillomatosis  (×40, H&E). (d) Pigmented seborrheic keratosis with basal
core was SCC (Fig. 6a–c), BCC (Fig. 7a–e), SK (Fig. 8a–d), KA
Fig.  9a–c), then controls respectively.
The intensity of ezrin expression in inﬂammatory cells
n  SCC ranged from 1 to 9 with mean ± SD 7.30 ± 2.63,
n  BCC, it ranged from 2 to 9 with mean ± SD 6.10 ± 2.38
n  SKs it ranged from 1 to 9 with mean ± SD 3.17 ± 2.99,
n  KA it ranged from 4 to 9 with mean ± SD 6.43 ± 2.51.
omparison among studied tumor groups revealed statis-
ically  signiﬁcant differences (P = 0.020) with highest value
n  SCC, BCC, KA, SK respectively. The intensity of ezrin
xpression in adjacent epidermis in SCC ranged from 2 to
 with mean ± SD 4.50 ± 2.68, in BCC, it ranged from 1 to
 with mean ± SD 3.17 ± 2.23, in SKs it ranged from 0 to
 with mean ± SD 1.33 ± 1.51, in KA it ranged from 1 to
 with mean ± SD 3.29 ± 2.06. Comparison among studied
umor  groups revealed statistically signiﬁcant differences
P  = 0.063) with highest value in SCC then KA, BCC and SK
espectively (Table 2).
The  membranous expression of ezrin expression in SCC
anged  from 0 to 50 with mean ± SD 7.50 ± 16.87, in BCC,
t  ranged from 0 to 5 with mean ± SD 1.00 ± 2.11, in SKs it
anged  from 0 to 80 with mean ± SD 19.17 ± 31.37, in KA
t  ranged from 0 to 70 with mean ± SD 20.71 ± 24.74 and
n  control group it ranged from 80 to 90 with mean ± SD
3.00  ± 4.47, there were statistically highly signiﬁcant dif-
erences  when comparing its expression between differentrn cyst (×40, H&E). (b) Basaloid seborrheic keratosis with basaloid cell
0, H&E). (c) Classic seborrhoeic keratosis with acanthosis, horn cysts and
entation and melanophages in the papillary dermis [arrow] (×40, H&E).
tumor  groups and controls (P = 0.001) with higher value
in  benign tumors which include SK than low-grade skin
tumor  as KA than malignant tumors which include SCC and
BCC.
The  cytoplasmic expression of ezrin expression in
SCC  ranged from 50 to 100 with mean ± SD 99.00 ± 2.11,
in  BCC, it ranged from 95 to 100 with mean ± SD
92.50 ± 16.87, in SKs it ranged from 20 to 100 with
mean ± SD 80.83 ± 31.37, in KA it ranged from 30 to 100
with  mean ± SD 79.29 ± 24.74 and in control group it
ranged from 10 to 20 with mean ± SD 17.00 ± 4.47, there
were  statistically highly signiﬁcant differences when com-
paring  its expression between different tumor groups and
controls  (P = 0.001) with higher value in malignant tumors
which  include BCC and SCC than benign tumors which
include SK and low-grade skin tumor as KA (Table 3).
4.  Discussion
Ezrin has been one of the new “hot spots” for explor-
ing tumor metastasis mechanisms in recent years. It is
the  predominant ERM protein of epithelial cells, where
it  is concentrated to the apical surface. It is involved
in a wide variety of cellular processes which func-
tion as cross-linkers between the plasma membrane and
the  cytoskeleton [12]. It has been found that, through
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Fig. 4. (a) Early stage keratoacanthoma with straight lower border [above the level of sweat glands], and hyaline eosinophilic keratinocytes forming the
lesion  and minimal inﬂammatory inﬁltrate (×40, H&E). (b) Late stage keratoacanthoma, with moderate epithelial involution and moderate inﬂammatory
inﬁltrate  (×40, H&E). (c) Keratoacanthoma [very late involution stage] with marked epithelial involution and dense inﬂammatory inﬁltrate, with straight
lower  border (×40 H&E).
Table 3
Comparison between membrane and cytoplasm percentage scores as regard ezrin expression in relation to type of the lesion.
Type of lesion Membrane percentage Cytoplasm percentage
Range Mean ± SD Range Mean ± SD
SCC 0–50 7.50 ± 16.87 50–100 99.00 ± 2.11
BCC  0–5 1.00 ± 2.11 95–100 92.50 ± 16.87
SK  0–80 19.17 ± 31.37 20–100 80.83 ± 31.37
KA  0–70 20.71 ± 24.74 30–100 79.29 ± 24.74
Control  80–90 83.00 ± 4.47 10–20 17.00 ± 4.47
Kruskal–Wallis  test 15.36 
P-value  0.001* 
** P value <0.001 was  considered highly signiﬁcant.
regulating adhesion molecules and signal transduction
pathways, ezrin is involved in cell–cell and cell–matrix
interactions, and might play an important role in the pro-
cess  of tumor cell invasion and metastasis [13]. Ezrin,
also known as cytovillin, is widely expressed in several
normal and malignant tissues of both epithelial and non-
epithelial origin. It is located in cell surface structures,
such as membrane rufﬂes, in various cell types. Stimula-
tion leads to ezrin phosphorylation and translocation to
the  rufﬂes, which in turn leads to increased motility and
proliferation [12].
In  the current study, there were signiﬁcant differ-
ences of ezrin expression when comparing different tumor112.2
0.001*
groups  and controls. These results were in agreement
with Park et al. [14], who  found the higher expression
of ezrin was markedly up regulated in SCC followed by
BCC,  Bowen’s disease, actinic keratosis, KA, SK and psori-
asis  vulgaris respectively. Darwish et al. [15] studied the
immunohistochemical expression of ezrin among BCC and
observed  markedly up regulation in all specimens of BCC
over  normal control. Also Abdou et al. [11] found increase
in  the ezrin expression in SCC and BCC than control skin
without signiﬁcant difference between tumors groups.
In  the present study, the intensity of ezrin expression in
inﬂammatory cells among studied groups revealed statisti-
cally  signiﬁcant differences with highest score in SCC. This









vated  ezrin travels underneath the cell membrane as a
F
d
sig. 5. Sweat gland cytoplasmic positivity for ezrin (×100, immunoperi-
xidase for ezrin) in normal skin.
esult was in agreement with many studies [14,16,17]. The
ntensity  of ezrin expression in adjacent epidermis among
tudied  groups revealed statistically signiﬁcant differences
ith highest mean value in BCC. By reviewing the literature,
o  available data about this issue was detected.
Both membranous expression and cytoplasmic expres-
ion  of ezrin among studied groups revealed statistically
ig. 6. (a) Well differentiated squamous cell carcinoma (grade I) with strong cyto
ifferentiated  squamous cell carcinoma (grade II) with strong cytoplasmic ezri
quamous cell carcinoma (grade III) with strong cytoplasmic expression of ezrin (nd Ultrastructure 2 (2014) 67–76 73
signiﬁcant differences. Most of normal specimens showed
prominent membranous expression of ezrin. The mean
value  of cell membrane percentage of ezrin was  higher
in  benign tumors than malignant tumors. While the mean
value  of cytoplasm percentage of ezrin was  higher in malig-
nant  tumors than benign tumors. So in the current study
KA  revealed mainly membranous expression of ezrin com-
pared  with cytoplasmic expression in SCC These results
were  in agreement with Park et al. [14] and Darwish et al.
[15].
Zeng  et al. [18] also reported a tendency of ezrin
to translocate from membrane to cytoplasm in the pro-
gression from normal epithelium to invasive carcinoma
of  the esophagus. This would corroborate the ﬁnding
of Fazioli et al. [19] who found a dramatic shift in the
localization of ezrin from membranous in normal mouse
ﬁbroblast to cytoplasmic in methylcholanthrene-induced
mouse sarcomas. The above observations imply that in
the  transformation and development of tumors, ezrin not
only  acts as a membrane–cytoskeletal linker to strengthen
the cells’ ability to retain their normal growth pattern but
also  is involved in cytoskeleton reorganization [20]. Acti-cross-linker between the membrane and the cytoskele-
ton. One explanation for the cytoplasmic ezrin expression
in  SCC cases is that the equilibrium between membrane
plasmic ezrin stain (×100, immunoperioxidase for ezrin). (b) Moderately
n stain (×100, immunoperioxidase for ezrin). (c) Poorly differentiated
×40, immunoperioxidase for ezrin).
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Fig. 7. (a) Nodular basal cell carcinoma with strong expression in lesional (neoplastic) cells and low expression in adjacent epithelium (×40, immunope-
rioxidase  for ezrin). (b) Basal cell carcinoma with moderate ezrin expression in the neoplastic cells and strong expression in the inﬂammatory inﬁltrate
(arrow)  (×40, immunoperioxidase for ezrin). (c) Superﬁcial basal cell carcinoma; strong positivity of the tumor cells in contrast to the adjacent epidermis
(×40,  immunoperioxidase for ezrin). (d) Morphea like basal cell carcinoma with strong cytoplasmic ezrin expression (×100, immunoperioxidase for ezrin).
(e)  Basal cell carcinoma with low positivity in (arrows) the peripheral neoplastic cells, high positivity in the central cells (a strike), high positivity in the
inﬂammatory  inﬁltrate and low positivity in adjacent epidermis (arrow heads) (×400, immunoperioxidase for ezrin).
Fig. 8. (a) Acanthotic seborrheic keratosis with mild cytoplasmic ezrin staining (×40, immunoperioxidase for ezrin). (b) Pigmented seborrheic keratosis
with  mild membranous positivity for ezrin (×400, immunoperioxidase for ezrin). (c) Basaloid seborrhoeic keratosis with moderate positivity for ezrin
located  in the superﬁcial layers (basaloid cells showed low positivity) (×40, immunoperioxidase for ezrin). (d) Classical seborrheic keratosis with strong
positivity  affecting the whole thickness [except the keratinous layer] (×40, immunoperioxidase for ezrin).
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iig. 9. (a) Early stage keratoacanthoma [lower straight border] positivi
zrin).  (b) Late involution stage of keratoacanthoma with strong positivity
or  ezrin). (c) Very late stage of keratoacanthoma with mild epithelial pos
nd cytoplasm is shifted to the cytoplasm by a decrease in
ctivating  signals or increase of inactivating signals [18].
ecently, baicalein was discovered to have anti-cancer
ctivity through inhibition of ezrin and phos-ezrin in A431
ells  [21].
.  Conclusion
Overall, the current study have shown that the change
f  cellular localization of ezrin in addition to its expres-
ion level in SCC, BCC, SK and KA lesions suggested that
he  localization of ezrin by immunohistochemical staining
ay  be used as a useful tool in predicting the prognosis
f such cases and may  be a useful tool in the differentia-
ion between SCC and KA. Ezrin could be useful predictor
f  tumor progression and to recognize patient groups that
eed  more aggressive treatment.
ecommendations
The study of ezrin expression on more different types of
kin  tumors may  open the door for further understanding
f the pathogenesis and progression of these tumors and
o  evaluate the encouraging effects of ezrin inhibitors as
ffective  therapy against various types of human tumors
ncluding BCC, SCC, SK and KA to determine which patientsrin and negative inﬂammatory inﬁltrate (×40, immunoperioxidase for
 the epithelial cells and the inﬂammatory cells (×40, immunoperioxidase
nd strong inﬂammatory positivity (×40, immunoperioxidase for ezrin).
might  potentially beneﬁt from ezrin inhibitor therapy. New
ﬁndings  were detected including, signiﬁcant correlation
between lesion score of ezrin expression and adjacent
epidermis in both benign and malignant tumor. Further
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